DE ROSA, VIVIANA
 Distribuzione geografica
Continente #
AS - Asia 1.162
NA - Nord America 860
EU - Europa 378
SA - Sud America 158
Continente sconosciuto - Info sul continente non disponibili 79
AF - Africa 12
OC - Oceania 1
Totale 2.650
Nazione #
US - Stati Uniti d'America 794
SG - Singapore 444
CN - Cina 224
HK - Hong Kong 214
IT - Italia 153
BR - Brasile 118
VN - Vietnam 88
FR - Francia 67
BD - Bangladesh 49
JP - Giappone 47
NL - Olanda 41
CA - Canada 36
KR - Corea 33
FI - Finlandia 28
DE - Germania 23
GB - Regno Unito 23
AR - Argentina 14
EC - Ecuador 13
MX - Messico 13
IN - India 12
ES - Italia 9
ID - Indonesia 8
CO - Colombia 7
IQ - Iraq 7
ZA - Sudafrica 7
IE - Irlanda 5
JO - Giordania 5
RU - Federazione Russa 5
TR - Turchia 5
CR - Costa Rica 4
MY - Malesia 4
UA - Ucraina 4
IL - Israele 3
JM - Giamaica 3
KH - Cambogia 3
LV - Lettonia 3
PH - Filippine 3
PL - Polonia 3
AT - Austria 2
HN - Honduras 2
MA - Marocco 2
NP - Nepal 2
PK - Pakistan 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
VC - Saint Vincent e Grenadine 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
BO - Bolivia 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
IM - Isola di Man 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
NI - Nicaragua 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SE - Svezia 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 2.571
Città #
Singapore 281
Hong Kong 213
Santa Clara 188
San Jose 96
Beijing 64
Hefei 61
Ashburn 58
Naples 56
Lauterbourg 49
Tokyo 42
Seoul 33
Los Angeles 28
Ho Chi Minh City 27
Hanoi 24
New York 18
Lappeenranta 16
Chicago 15
Casandrino 13
Frankfurt am Main 11
Helsinki 11
São Paulo 11
Council Bluffs 9
Buffalo 8
Rome 8
Milan 7
Atlanta 6
Belleville 6
Boardman 6
Brooklyn 6
Mexico City 6
Dallas 5
Des Moines 5
Dublin 5
Orem 5
Amman 4
Amsterdam 4
Da Nang 4
Düsseldorf 4
Guayaquil 4
Hangzhou 4
London 4
Montreal 4
Phoenix 4
Quito 4
Shanghai 4
Toronto 4
Abbeville 3
Baghdad 3
Bauru 3
Belo Horizonte 3
Bengaluru 3
Boston 3
Buenos Aires 3
Carapicuíba 3
Chennai 3
Columbus 3
Haiphong 3
Istanbul 3
Johannesburg 3
Minamishinagawa 3
Paris 3
Philadelphia 3
Phnom Penh 3
Poplar 3
Ribeirão Preto 3
Riga 3
San Antonio 3
Seattle 3
Washington 3
Abingdon 2
Alajuela 2
Baltimore 2
Biên Hòa 2
Bogotá 2
Bonito 2
Brasília 2
Bratislava 2
Can Tho 2
Charlotte 2
Clinton Township 2
Columbia 2
Covina 2
Erbil 2
Falkenstein 2
Florence 2
Fort Lauderdale 2
Fortaleza 2
Ha Long 2
Hammond 2
Houston 2
Hòa Bình 2
Hải Dương 2
Jackson 2
Keyport 2
Kingstown 2
Kuala Lumpur 2
Lajeado 2
Lancaster 2
Las Vegas 2
Maceió 2
Totale 1.576
Nome #
Monitoring Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by 18F-FLT PET/CT 97
Early reduction of 18F-FDG uptake in non-small lung cancer treated with EGFR tyrosine kinase inhibitors reflects reversal of Warburg effect and reactivation of oxidative phosphorylation. 92
Changes of Glycolytic Pathway in Response to Efficient Inhibition of EGFR Signaling in Non-small Cell Lung Cancer (NSCLC) 91
Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study 80
18F-FLT PET/CT imaging and inhibition of multiple signaling pathways downstream EGFR and MET receptors in resistant NSCLC 79
18F-FLT PET/CT for Detection of Functional Cross-talk between MET and EGFR in Non-small Cell Lung Cancer Resistant to EGFR Inhibitors 78
Molecular mechanisms of decreased aerobic glycolysis in non-small lung cancer treated with EGFR tyrosine kinase inhibitors. European Society for Molecular Imaging Meeting 77
ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors 75
Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by F-18-fluorothymidine 72
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 71
Exosome-like Systems: From Therapies to Vaccination for Cancer Treatment and Prevention-Exploring the State of the Art 70
Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy 67
Multimodal imaging of tumor invasion by targeting integrin ?v?3 in a preclinical model of lung metastasis 64
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 64
Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER–Mitochondria Interface in Oncogene-Driven NSCLC 64
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 63
Changes of glycolytic pathway and upregulation of oxidative phosphorylation in BCR-ABL-driven human leukemia cells treated with imatinib 61
A reversible shift of driver dependence from egfr to notch1 in non-small cell lung cancer as a cause of resistance to tyrosine kinase inhibitors 61
Preclinical imaging for targeting cancer immune evasion 59
Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells 59
Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells 57
Preclinical Imaging in Targeted Cancer Therapies 54
Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins 51
Notch1-dependent targets in cancer stem cell resistance to EGFR inhibitors in oncogene-driven non-small cell lung cancer 48
Coordinate modulation of glycolytic enzymes and OXPHOS by imatinib in BCR-ABL driven chronic myelogenous leukemia cells 48
Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer 47
Monitoring the effects of combined treatment with EGFR and MET inhibitors in non-small cell lung cancer and synergy quantification by 18F-FLT PET/CT 46
Early F-18-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 44
18F-FLT PET/CT imaging of inositol trisphosphate receptor type 3-mediated enhancement of EGFR and MET co-targeting efficacy in non-small cell lung cancer 44
Preclinical imaging in oncology: advances and perspectives 42
Small animal SPECT with 99m-Tc-Hynic-annexin V for detection of non-small cell lung cancer resistance to EGFR antagonists and its reversal by Bcl-xL inhibitors 41
Effect of IL-1β on NSCLC-Derived Small Extracellular Vesicles as Actors in Mediating Cancer Progression and Evading Immune System 40
18F-FLT PET/CT as a surrogate biomarker for synergy quantification in EGFR targeted combination therapy of NSCLC 40
18F-FLT PET/CT to Detect Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer. 36
Combination of Abeta secretion and oxidative stress in an Alzheimer-like cell line leads to the over-expression of the nucleotide excision repair proteins DDB2 and XPC 35
Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography 35
Neutrophil extracellular traps as drivers of epithelial-mesenchymal transition in cancer cells 32
18F-FLT PET/CT to detect reversal of EGFR TKI resistance due to MET amplification by MET inhibitors in NSCLC 32
Effect of Soluble Factors Released from Porcine Freeze-Dried Lung Tissue (FDLT) on Modulation of Cell Growth and EMT Signature in Non-Small Cell Lung Cancer (NSCLC)—A Preliminary In Vitro Study 31
Combined Imaging with 18F-FLT PET/CT and 99m-Tc-Hynic-Annexin V SPECT for Personalized Therapy with EGFR Antagonists and Bcl-xL Inhibitors in Non-Small Cell Lung Cancer 31
Small animal SPECT with 99m-Tc-Hynic-annexin V for detection of non-small cell lung cancer resistance to EGFR antagonists and its reversal by Bcl-xL inhibitors 31
18F-FLT PET/CT to Detect Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer 30
Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer 30
18F-FLT PET/CTas a surrogate biomarker for synergy quantification in EGFR targeted combination therapy of NSCLC 30
Synergistic effects of oncogene inhibition and pyruvate dehydrogenase kinase blockade in resistant NSCLC cells 30
Does a role for selenium in DNA damage repair explain apparent controversies in its use in chemoprevention? 29
[18]F-FLT PET-CT to detect reversal of EGFR TKI resistance due to MET amplification by MET inhibitors in NSCLC. 28
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 27
Low doses of selenium specifically stimulate the repair of oxidative DNA damage in LNCaP prostate cancer cells 27
Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer 24
Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in NSCLC 24
Alzheimer's Disease-Associated Neurotoxic Peptide Amyloid-B Impairs Base Excision Repair in Human Neuroblastoma Cells 23
Addition of metformin to anti-PD-1/PD-L1 drugs activates antitumor immune response in peripheral immune cells of NSCLC patients 23
Novel applications of liquid Biopsy: Comprehensive methodology for circulating biomarker exploration in peripheral blood 16
Totale 2.650
Categoria #
all - tutte 8.524
article - articoli 7.792
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.316


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202435 0 0 0 0 0 0 0 0 5 8 7 15
2024/2025861 15 14 79 42 195 40 1 58 54 62 156 145
2025/20261.412 62 95 73 136 328 90 215 59 116 96 63 79
2026/2027342 83 79 180 0 0 0 0 0 0 0 0 0
Totale 2.650